|
Concord Drugs Ltd.
|
Ratio Analysis
|
|
|
You can view the
Ratio Analysis
for the last 5 years.
|
Market Cap. (Rs.)
|
112.04 Cr.
|
P/BV
|
3.02
|
Book Value (Rs.)
|
28.13
|
|
52 Week High/Low (Rs.)
|
93/26
|
FV/ML
|
10/1
|
P/E(X)
|
333.49
|
|
Bookclosure
|
30/09/2024
|
EPS (Rs.)
|
0.26
|
Div Yield (%)
|
0.00
|
|
| Months | 12 | 12 | 12 |
| Source Of Info (AR = Annual Report, PR = Press Release) | AR | AR | AR |
| FaceValue | 10.00 | 10.00 | 10.00 |
| | | | |
| PER SHARE RATIOS | | | |
| | | | |
| Basic EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Diluted EPS (Rs.) | 0.34 | 0.47 | 1.06 |
| Cash EPS (Rs.) | 1.77 | 2.03 | 2.80 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 34.11 | 33.82 | 34.03 |
| Revenue From Operations / Share (Rs.) | 45.24 | 44.92 | 55.91 |
| PBDIT / Share (Rs.) | 4.15 | 4.05 | 4.92 |
| PBIT / Share (Rs.) | 2.72 | 2.50 | 3.17 |
| PBT / Share (Rs.) | 0.69 | 0.62 | 1.34 |
| Net Profit / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| NP After MI And SOA / Share (Rs.) | 0.33 | 0.47 | 1.06 |
| | | | |
| PROFITABILITY RATIOS | | | |
| | | | |
| PBDIT Margin (%) | 9.16 | 9.01 | 8.79 |
| PBIT Margin (%) | 6.00 | 5.55 | 5.67 |
| PBT Margin (%) | 1.52 | 1.40 | 2.39 |
| Net Profit Margin (%) | 0.74 | 1.05 | 1.89 |
| NP After MI And SOA Margin (%) | 0.74 | 1.05 | 1.89 |
| Return on Networth / Equity (%) | 0.98 | 1.39 | 3.10 |
| Return on Capital Employeed (%) | 6.97 | 6.66 | 8.07 |
| Return On Assets (%) | 0.51 | 0.80 | 1.69 |
| Long Term Debt / Equity (X) | 0.03 | 0.01 | 0.06 |
| Total Debt / Equity (X) | 0.50 | 0.49 | 0.50 |
| Asset Turnover Ratio (%) | 0.73 | 0.76 | 0.00 |
| | | | |
| LIQUIDITY RATIOS | | | |
| | | | |
| Current Ratio (X) | 1.56 | 2.09 | 2.01 |
| Quick Ratio (X) | 0.59 | 1.02 | 1.08 |
| Inventory Turnover Ratio (X) | 1.88 | 2.09 | 0.00 |
| | | | |
| COVERAGE RATIOS | | | |
| | | | |
| Interest Coverage Ratio (%) | 2.05 | 2.17 | 2.68 |
| Interest Coverage Ratio (Post Tax) (%) | 1.17 | 1.25 | 1.58 |
| | | | |
| VALUATION RATIOS | | | |
| | | | |
| Enterprise Value (Cr.) | 48.05 | 51.59 | 41.61 |
| EV / Net Operating Revenue (X) | 1.06 | 1.15 | 0.79 |
| EV / EBITDA (X) | 11.58 | 12.73 | 9.08 |
| MarketCap / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| Price / BV (X) | 0.91 | 1.04 | 0.80 |
| Price / Net Operating Revenue (X) | 0.68 | 0.78 | 0.49 |
| EarningsYield | 0.01 | 0.01 | 0.03 |
